Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS' Purchase Of Amira: When An Acquisition Is Really An Asset Sale

This article was originally published in Start Up

Executive Summary

Bristol-Myers Squibb Co.'s purchase of Amira Pharmaceuticals Inc. for $325 million upfront and another $150 million in downstream milestones shows that prior licensing deals and multiple programs in a pipeline don't necessarily curb a start-up's acquisition potential, provided investors are thinking smartly about deal structures that create separate value streams for the various products in the portfolio.

You may also be interested in...



Here To Stay: Inception Sciences Shows Why Build-To-Buy Works

Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.

Versant Launches Inception IBD, A New Company With Old Roots

Versant and Celgene have partnered again to launch a build-to-buy biotech, this time focusing on inflammatory bowel disease.

Versant Ventures Looks To Canada, Europe For New Deals

Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel